Tangella Adarsh Vardhan, Gajre Ashwin, Kantheti Vivek Varma
Internal Medicine, Andhra Medical College and King George Hospital, Visakhapatnam, IND.
Internal Medicine, Lokmanya Tilak Municipal Medical College, Mumbai, IND.
Cureus. 2023 Sep 6;15(9):e44802. doi: 10.7759/cureus.44802. eCollection 2023 Sep.
Acute myeloid leukemia (AML) arises from immature myeloid progenitors, resulting in a stem-cell-like proliferative state. This leads to excessive pools of immature cells that cannot function, which usually happens at the cost of the production of mature functional cells, leading to deleterious consequences. The management of AML has intensified as newer targeted therapies have come into existence owing to deeper genetic analysis of the disease and patients. Isocitrate dehydrogenase (IDH) is a cytosolic enzyme that is a part of the Krebs cycle and is extremely important in maintaining the homeostasis of the cell. It is produced by two different genes: IDH1 and IDH2. Ivosidenib has been associated with IDH1 inhibition and has been studied in numerous cancers. This review highlights the studies that have dealt with ivosidenib, an IDH1 inhibitor, in AML, the side effect profile, and the possible future course of the drug. After a scoping review of the available literature, we have identified that studies have consistently shown positive outcomes and that ivosidenib is a promising avenue for the management of AML. But it also has to be kept in mind that resistance to IDH inhibitors is on the rise, and the need to identify ways to circumvent this is to be addressed.
急性髓系白血病（AML）起源于未成熟的髓系祖细胞，导致一种类似干细胞的增殖状态。这会导致大量无法发挥功能的未成熟细胞积聚，而这通常是以牺牲成熟功能细胞的产生为代价的，从而产生有害后果。随着对该疾病和患者进行更深入的基因分析，新的靶向治疗方法问世，AML的治疗得到了加强。异柠檬酸脱氢酶（IDH）是一种胞质酶，是三羧酸循环的一部分，在维持细胞内稳态方面极为重要。它由两个不同的基因IDH1和IDH2产生。艾伏尼布与IDH1抑制有关，并已在多种癌症中进行了研究。本综述重点介绍了有关IDH1抑制剂艾伏尼布在AML中的研究、副作用情况以及该药物未来可能的发展方向。在对现有文献进行范围综述后，我们发现研究一致显示出积极的结果，并且艾伏尼布是治疗AML的一个有前景的途径。但也必须牢记，对IDH抑制剂的耐药性正在上升，需要找到规避这种情况的方法。
